Comparative Pharmacology
Head-to-head clinical analysis: DIUPRES 250 versus SER AP ES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIUPRES 250 versus SER AP ES.
DIUPRES-250 vs SER-AP-ES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diupres-250 is a combination of hydrochlorothiazide (a thiazide diuretic) and reserpine (a Rauwolfia alkaloid). Hydrochlorothiazide inhibits the Na+/Cl- cotransporter in the distal convoluted tubule of the kidney, increasing excretion of sodium and water. Reserpine depletes catecholamines and serotonin from presynaptic nerve terminals by irreversibly binding to vesicular monoamine transporter (VMAT), leading to reduced sympathetic outflow and hypotension.
SER-AP-ES is a combination product containing reserpine (depletes catecholamines from adrenergic nerve endings), hydralazine (direct vasodilation via smooth muscle relaxation), and hydrochlorothiazide (thiazide diuretic that inhibits sodium reabsorption in distal tubules).
1 tablet (containing 250 mg chlorothiazide and 0.125 mg reserpine) orally once daily, increased to 2 tablets daily if needed.
SER-AP-ES is a combination antihypertensive tablet containing reserpine 0.1 mg, hydralazine hydrochloride 25 mg, and hydrochlorothiazide 15 mg. Usual adult dose: one tablet orally twice daily. Increase as needed to a maximum of two tablets twice daily.
None Documented
None Documented
Hydroflumethiazide: 6-18 hours (prolonged in renal impairment). Reserpine: 50-100 hours (biphasic; terminal phase).
Reserpine: 50-100h (terminal); hydralazine: 2-8h (slow acetylators 4-8h, fast 2-4h); hydrochlorothiazide: 6-15h. Context: reserpine's long t½ accounts for prolonged effects; hydralazine requires dose adjustment for acetylator status.
Renal: approximately 50% of hydroflumethiazide is excreted unchanged in urine; reserpine is extensively metabolized with <1% excreted unchanged. Fecal: minimal.
Renal: 30-40% unchanged reserpine; 60-70% as metabolites (hydralazine: 50% renal, 15% fecal; hydrochlorothiazide: 95% renal unchanged).
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination